ErbB/HER receptors play essential roles in propagating signals that regulate cell proliferation, differentiation, motility, and apoptosis. Significantly, aberrant regulation of the ErbB/HER family of receptor tyrosine kinases and their ligands is a common occurrence in many human tumors. Indeed, EGFR, HER2, and HER3 have been diagnostically and therapeutically validated as targets in a wide variety of human malignancies such as lung, colorectal, breast, head and neck, gastric and pancreatic cancers. Therefore, novel protein biopharmaceuticals that comprehensively target ErbB/HER family members could have significant applications in targeted diagnosis and therapy of different types of cancer. This project addresses a critical need for developing cost-effective targeting ligands that recognize and bind HER family members with desired avidity and multispecificity. The project is directed at using a powerful in vitro protein selection method called mRNA display to evolve single domain antibodies (SDAs) with human origin that tightly and specifically bind to the extracellular domain of EFRG, HER2 or HER3, respectively, from a human SDA domain library with an unusually high diversity. The resulting monomeric SDAs will be used as the basis for the generation of heterodimeric SDAs that bind to a HER member of interest at two nonoverlapping epitopes with synergistic avidity effect. In addition, we will develop an efficient and universal self-assembly system that allows for reversible and controllable loading of HER-binding SDAs to nanoparticles to acquire desired multispecificity. The resulting SDAs would have a number of advantages, including high target-binding affinity, ease to achieve desired avidity, multivalency and multispecificity, minimal immunogenicity due to human origin, small size for better tissue penetration, in addition to significantly reduced manufacturing costs due to high expression levels in bacteria. The simplicity and stability of these SDAs also greatly facilitate their conjugation with various nanoparticles for translational applications. The resulting SDAs will be examined in vivo in pancreatic ductal adenocarcinoma (PDAC) xenograft animal models by targeted delivery of nanoparticles containing siRNAs against several metastasis signature genes that are important for PDAC tumorigenesis and metastasis. The success of the project will lead to the development of cost-effective, targeted biopharmaceuticals for cancer diagnosis and therapy.

Public Health Relevance

Aberrant regulation of the ErbB/HER family of receptor tyrosine kinases and their ligands is a common occurrence in many human malignancies such as lung, colorectal, breast, head and neck, gastric and pancreatic cancers. It is of great importance to develop targeting ligands that can comprehensively target ErbB/HER family members for targeted diagnosis and therapy. This project is directed at developing the next generation single domain antibodies with human origin that tightly and specifically bind ErbB/HER family members with desired avidity and multispecificity. The resulting targeting ligands can be used for the targeted delivery of nanoparticles for translational applications. The success of the project will lead to the development of cost-effective, targeted biopharmaceuticals for cancer diagnosis and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
4R01CA157738-05
Application #
8985658
Study Section
Nanotechnology Study Section (NANO)
Program Officer
Yovandich, Jason L
Project Start
2011-12-09
Project End
2017-11-30
Budget Start
2015-12-01
Budget End
2017-11-30
Support Year
5
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Zhou, Jingying; Liu, Man; Sun, Hanyong et al. (2018) Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 67:931-944
Liu, Qi; Zhu, Hongda; Tiruthani, Karthik et al. (2018) Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. ACS Nano 12:1250-1261
Song, Wantong; Shen, Limei; Wang, Ying et al. (2018) Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun 9:2237
Miao, Lei; Li, Jingjing; Liu, Qi et al. (2017) Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano 11:8690-8706
Goodwin, Tyler J; Shen, Limei; Hu, Mengying et al. (2017) Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials 141:260-271
Wang, Hui; Vilela, Marco; Winkler, Andreas et al. (2016) LOVTRAP: an optogenetic system for photoinduced protein dissociation. Nat Methods 13:755-8
Goodwin, Tyler J; Zhou, Yingqiu; Musetti, Sara N et al. (2016) Local and transient gene expression primes the liver to resist cancer metastasis. Sci Transl Med 8:364ra153
Friedman, Adam D; Kim, Dongwook; Liu, Rihe (2015) Highly stable aptamers selected from a 2'-fully modified fGmH RNA library for targeting biomaterials. Biomaterials 36:110-23
Kim, Dongwook; Friedman, Adam D; Liu, Rihe (2014) Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials 35:6026-36
Valencia, C Alexander; Zou, Jianwei; Liu, Rihe (2013) In vitro selection of proteins with desired characteristics using mRNA-display. Methods 60:55-69

Showing the most recent 10 out of 13 publications